FORM 4

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	2. Issuer Name and Ticker or Trading Symbol Emmaus Life Sciences, Inc. [EMMA]					S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X. Director Y. Officer (rive title below) Other (check person)				
3. Date of Earlies 03/26/2020	3. Date of Earliest Transaction (Month/Day/Year) 03/26/2020					Vice Chairman & COO				
4. If Amendment	4. If Amendment, Date Original Filed(Month/Day/Year)					_X_ Form fil	ed by One Repo	orting Person		able Line)
Т	able I - No	ı-Dei	rivative S	ecuriti	ies Acqı	iired, Disp	osed of, or I	Beneficially	Owned	
Execution Date, if Year) any	if Code (Instr. 8)		tion 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
	P	V		(D)	\$ 1.23 (1)	25,200			(Instr. 4)	By FMT CO CUST IRA FBO Willis Lee
	P		3,300	A	\$ 1.05 (2)	28,500			I	By FMT CO CUST IRA FBO Willis Lee
						215,624			D	
						75,761			I	By Pensco Trust Company LLC FBO Willis C. Lee
securities beneficially o		Pers	sons wh tained ir	o resp	form ar	e not requ	ired to res	spond unl	ess	C 1474 (9-02)
e II - Derivative Securit	ties Acquir	ed, D	isposed o	f, or B	Seneficia curities	ally Owned				
emed 4. on Date, if Transaction Code	5. Number of	6. D and (Mo	Oate Exerc Expiratio	isable n Date	7. T Am Und Sec	7. Title and Amount of Derivative Derivative Securities (Instr. 3 and 4) 8. Price of Derivative Derivative Securities (Instr. 5) 9. Number of Derivative Securities Gecurities Gecurity Securities Peneficially Downed Security Owned Following Reported Transaction(s)		Owner Form of Deriva Securit Direct or Indi	Beneficial Ownership y: (Instr. 4)	
	Emmaus Life 3. Date of Earlies 03/26/2020 4. If Amendment 2A. Deemed Execution Date, if any (Month/Day/Year) 0 10 10 10 11 12 12 13 14 15 15 16 17 17 18 18 19 19 19 19 19 19 19 19	Emmaus Life Sciences, 3. Date of Earliest Transaction O3/26/2020 4. If Amendment, Date Originary In Execution Date, if any (Month/Day/Year) 10. P 10. P 10. P 11. Derivative Securities Acquire (e.g., puts, calls, warrants, open of code (Instr. 8) 12. Derivative Securities Acquire (e.g., puts, calls, warrants, open of code (Instr. 8) 13. Transact Code (Instr. 8) 14. Code 15. Number of Derivative Securities Acquire (A) or Disposed of (D) (Instr. 3, or Disposed of (D) (Instr. 4) (Instr. 4	Emmaus Life Sciences, Inc. 3. Date of Earliest Transaction (Mod 103/26/2020) 4. If Amendment, Date Original Form Part of Execution Date, if any (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) Code (Instr. 8) Personation Part of Executities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personate process of the securities beneficially owned directly or personat	Emmaus Life Sciences, Inc. [EMM] 3. Date of Earliest Transaction (Month/Day) 03/26/2020 4. If Amendment, Date Original Filed(Month) Table I - Non-Derivative Securition Date, if any (Month/Day/Year) O P 3,500 P 3,500 P 3,500 P 3,300 of securities beneficially owned directly or indirectly or indirectly of the form distribution Date, if the form distribution Date, if of Code (P.g., puts, calls, warrants, options, convertine of Date, if Transaction Code (Instr. 8) It I - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, and Expiration (Month/Day/Year) It I - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, and Expiration (Month/Day/Year)	Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earliest Transaction (Month/Day/Year) 03/26/2020 4. If Amendment, Date Original Filed(Month/Day/Year) Table I - Non-Derivative Securit Execution Date, if of Code (Instr. 8) O P 3,500 A P 3,500 A O P 3,300 A O P 3,100 A O P 3,	Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) P	Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earliest Transaction (Month/Day/Year) 00/3/26/2020 4. If Amendment, Date Original Filed(Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disponsion (Instr. 3) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3 at original Price (Instr. 3)) Code V Amount (D) Price P 3,500 A 1.23 25,200 10 P 3,300 A 1.05 28,500 215,624 Total Persons who respond to the colled contained in this form are not required from displays a currently valid (Instr. 8) Total Persons who respond to the colled contained in this form are not required from displays a currently valid (Instr. 8) Total Persons who respond to the colled contained in this form are not required from displays a currently valid (Instr. 8) Title and Alpha Persons who respond to the colled contained in this form are not required from displays a currently valid (Instr. 8) Total Persons who respond to the colled contained in this form are not required from displays a currently valid (Instr. 8) Title and Expriation Date (Instr. 8) Title and Alpha Persons who respond to the colled contained in this form are not required from displays a currently valid (Instr. 3) Title and Alpha Persons who respond to the colled contained in this form are not required from displays a currently valid (Instr. 3) Title and Alpha Persons who respond to the colled contained in this form are not required from displays a currently valid (Instr. 3) Total Persons who respond to the colled contained in this form are not required (Instr. 8) Total Persons who respond to the colled contained in this form are not required (Instr. 8) Total Persons who respond to the colled contained in this form are not required (Instr. 8) Total Persons who respond to the colled contained in this form are not required (Instr. 8) Total Persons who respond to the colled contained in this form are not required (Instr. 8)	Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3) Code P 3. 3,500 A 1.23 25,200 1.215,624 Persons who respond to the collection of infontational in this form are not required to reside in this form are not required to resident in this form are not required to resi	Emmaus Life Sciences, Inc. [EMMA] 3. Jate of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Following (Instr. 3. 4 and 5) P	Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earlies Transaction (Month/Day/Year) 4. If Amendment, Date Original FiledMonth/Day/Year) 4. If Amendment, Date Original FiledMonth/Day/Year) 5. Amount of Sciences Applies Reported Fransaction (Month/Day/Year) 6. Individual or Joint/Group FilingCheck Applies Received to Date, Joseph Code (Month/Day/Year) 7. Execution Date, Jif (Code (Month/Day/Year) 8. Amount of Sciences (Month/Day/Year) 8. Amount of Sciences (Month/Day/Year) 9. Amount of Date (Month/Day/Year) 10. Price (Month/Day/Year) 11. Amount of Sciences (Month/Day/Year) 12. Amount of Sciences (Month/Day/Year) 13. Amount of Sciences (Month/Day/Year) 14. Sciences (Month/Day/Year) 15. Amount of Sciences (Month/Day/Year) 16. Individual or Joint/Group FilingCheck Applies (Month/Day/Year) 16. Amount of Sciences (Month/Day/Year) 17. Amount of Sciences (Month/Day/Year) 18. Sciences (Month/Day/Year) 19. Amount of Month/Day/Year) 19. Amount of Sciences (Month/Day/Year) 10. Price (Month/Day/Year) 10. Price (Month/Day/Year) 10. Amount of Month/Day/Year) 10. Amount of Sciences (Month/Day/Year) 10. Amount of Month/Day/Year) 11. January (Month/Day/Year) 12. Sciences (Month/Day/Year) 13. Transaction (Month/Day/Year) 14. Sciences (Month/Day/Year) 15. Amount of Sciences (Month/Day/Year) 16. Individual or Joint/Group FilingCheck Applies (Month/Day/Year) 16. Amount of Sciences (Month/Day/Year) 17. Title and Month of M

	Code	V	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
--	------	---	-----	--	---------------------	--------------------	-------	--	--	--	--	--	--

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
LEE WILLIS C 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE, CA 90503	X		Vice Chairman & COO					

Signatures

Willis C. Lee	03/30/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.15 to \$1.34, inclusive. The reporting person (1) undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.
- (2) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.99 to \$1.10, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.